On September 17, Santos, EVP at Rigel Pharmaceuticals (NASDAQ:RIGL), executed a strategic insider move by acquiring stock options for 7,394 shares.
What Happened: In a recent Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday, Santos, EVP at Rigel Pharmaceuticals, acquired 7,394 stock options for RIGL with an exercise price of $22.49 per share.
During Thursday's morning session, Rigel Pharmaceuticals shares up by 1.55%, currently priced at $34.75. Considering the current price, Santos's 7,394 shares have a total value of $90,650.
About Rigel Pharmaceuticals
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Rigel Pharmaceuticals's Financial Performance
Revenue Growth: Over the 3 months period, Rigel Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 176.01% as of 30 June, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Insights into Profitability:
-
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 95.57%, indicating potential difficulties in maintaining profitability compared to its peers.
-
Earnings per Share (EPS): Rigel Pharmaceuticals's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 3.33.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.75, caution is advised due to increased financial risk.
Analyzing Market Valuation:
-
Price to Earnings (P/E) Ratio: Rigel Pharmaceuticals's P/E ratio of 6.3 is below the industry average, suggesting the stock may be undervalued.
-
Price to Sales (P/S) Ratio: The P/S ratio of 2.3 is lower than the industry average, implying a discounted valuation for Rigel Pharmaceuticals's stock in relation to sales performance.
-
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): The company's EV/EBITDA ratio 5.18 is below the industry average, indicating that it may be relatively undervalued compared to peers.
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
Why Insider Transactions Are Key in Investment Decisions
Insider transactions, although significant, should be considered within the larger context of market analysis and trends.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
Exploring Key Transaction Codes
When it comes to transactions, investors tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
Check Out The Full List Of Rigel Pharmaceuticals's Insider Trades.
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. Click here for access.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
